摘要
目的探讨前蛋白转化酶枯草溶菌素9抑制剂在急性冠状动脉综合征患者中的应用。方法选取2018年6月~2019年7月我院收治的60例ACS患者,根据用药方案不同分为观察组和对照组,每组30例,观察组给予PCSK9抑制剂进行治疗,对照组给予阿托伐他汀联合依折麦布进行治疗,评价两组总胆固醇、甘油三酯、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、超敏C反应蛋白水平与心血管不良事件发生率。结果治疗前两组TC、TG、LDL-C、HDL-C、hs-CRP值比较无统计学意义(P>0.05);治疗后观察组TC值(4.01±0.90)mmol/L、TG值(1.21±0.20)mmol/L、LDL-C值(2.72±0.97)mmol/L、HDL-C值(1.30±0.28)mmol/L、hs-CRP值(2.46±0.21)mmol/L,对照组TC值(5.00±0.74)mmol/L、TG值(1.98±0.22)mmol/L、LDL-C值(3.32±1.00)mmol/L、HDL-C值(1.14±0.20)mmol/L、hs-CRP值(5.46±1.72)mmol/L;观察组治疗后TC、TG、LDL-C、HDL-C、hs-CRP值均优于对照组(P<0.05)。观察组心脑血管不良事件发生率为6.67%,低于对照组的26.67%(P<0.05)。结论 PCSK9抑制剂在ACS患者中应用可有效发挥降脂效果,可积极预防心血管不良事件的发生。
Objective To discuss the application of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with acute coronary syndrome Methods Sixty patients with ASC treated in our hospital from June 2018 to July 2019 were enrolled and divided into the observation group and the control group, with each group of 30 patients according to the therapeutic regimen. PCSK9 inhibitor therapy was given to the observation group, and atorvastatin combined with ezetimibe therapy was given to the control group. The levels of total cholesterol, triglyceride, low density lipoprotein cholesterol, high density lipoprotein cholesterol, hypersensitive C-reactive protein and the incidences of cardiovascular adverse events in the two groups were evaluated. Results It was found that there was no statistical significance in the TC, TG, LDL-C, HDL-C and hs-CRP value before treatment between the two groups(P>0.05). After treatment, TC value was(4.0±0.90)mmol/L, TG value was(1.21±0.20)mmol/L, LDL-C value was(2.72±0.97)mmol/L, HDL-C value was(1.30±0.28)mmol/L, and hs-CRP value was(2.46±0.21)mmol/L in the observation group. After treatment, TC value was(5.00±0.74)mmol/L, TG value was(1.98±0.22)mmol/L, LDL-C value was(3.32±1.00)mmol/L, HDL-C value was(1.14±0.20)mmol/L, and hs-CRP value was(5.46±1.72)mmol/L in the control group. The values of TC, TG, LDL-C, HDL-C and hs-CRP after treatment in the observation group were all better than those in the control group(P<0.05). The incidence of cardiovascular adverse events in the observation group was 6.67%, which was lower than that in the control group(26.67%)(P<0.05). Conclusion The application of PCSK9 inhibitors in patients with ACS can effectively lower lipid and actively prevent cardiovascular adverse events.
作者
黄舒洁
陈威
HUANG Shujie;CHEN Wei(Department of Cardiovascular Medicine,Fujian Provincial Hospital,Fuzhou350001,China)
出处
《中国现代医生》
2020年第3期16-18,共3页
China Modern Doctor
作者简介
通讯作者:陈威。
